Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Here's Why You Should Invest In Athenaheath Stock Right Now

Published 03/26/2018, 11:00 PM
Updated 07/09/2023, 06:31 AM

On Mar 26, we issued an updated research report on athenahealth Inc (NASDAQ:ATHN) . The company’s strong product portfolio, solid network expansion strategies and unique business model are tailwinds.

Consequently, athenahealth is one of the top-performing stocks in the MedTech sector. The stock sports a Zacks Rank #1 (Strong Buy). Further, an improvement in share price and strong fundamentals indicate analyst’s bullish sentiments.

Price Performance & Estimate Revision Trend

Estimates for athenahealth have moved upward over the past 60 days, reflecting analysts’ optimism in the stock. The Zacks Consensus Estimate for 2018 and 2019 earnings have been revised 29.8% and 25.8% upward to $3.79 and $4.49, respectively.

Shares of this company have outperformed the industry in a year’s time. The stock has returned 25.3% compared with the industry’s rally of 6.5%.

athenahealth, Inc. Price and Consensus

Let’s focus on the factors that make athenahealth an attractive pick for investors.

Favorable Factors

athenahealth’s portfolio comprises a wide array of products that include electronic health records, revenue cycle management, medical billing, patient engagement, care coordination, population health management and Epocrates.

By the end of the fourth quarter of 2017, athenahealth launched its first machine-learning model to automate faxes. The company also piloted services like authorization management, which is likely to expand its client base throughout 2018.

athenaInsight, an online news hub that reports on U.S. healthcare activities and trends of healthcare providers and de-identified patients, has been fortifying the company’s footprint.

In 2017, athenahealth expanded its patient record sharing capabilities with CommonWell and Carequality.

For full-year 2018, the company expects adjusted operating margin in the range of 16-17%. The company has not provided any guidance for adjusted earnings. athenahealth estimates total revenues in the range of $1,310-$1,380 million.

Other Key Picks

A few other top-ranked stocks in the broader medical sector are Bio-Rad Laboratories (NYSE:BIO) , Varian Medical Systems, Inc. (NYSE:VAR) and PerkinElmer (NYSE:PKI) .

Bio-Rad Laboratories sports a Zacks Rank of #1. You can see the complete list of today’s Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 20%.

Varian Medical has a long-term expected earnings growth rate of 8%. The stock carries a Zacks Rank of 2 (Buy).

PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>



athenahealth, Inc. (ATHN): Free Stock Analysis Report

PerkinElmer, Inc. (PKI): Free Stock Analysis Report

Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report

Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.